Newsroom
Sorted by: Latest
-
OBERON AIM VCT PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Oberon AIM VCT Net Asset Value (s) As at the close on the 31ST December 2025 and based on mid market prices, the net asset value of the Oberon AIM VCT was 27.54p per share....
-
Kovacich Snipes Johnson Partners Repeat on Lawdragon Leading Lawyers List
GREAT FALLS, Mont.--(BUSINESS WIRE)--For a second consecutive year, Kovacich Snipes Johnson partners Mark Kovacich and Ben Snipes are the only Montana-based lawyers included in the Lawdragon 500 Leading Lawyers in America legal guide. Mr. Kovacich and Mr. Snipes are both recognized for excellence in plaintiff personal injury/mass torts litigation in the 2026 edition. Dominated by major market attorneys, the list nonetheless takes note of the work done by attorneys nationwide “who inspire us and...
-
Fabentech obtient l'autorisation de mise sur le marché de Ricimed®, un antidote contre l'empoisonnement à la ricine
LYON, France--(BUSINESS WIRE)--Fabentech, société biopharmaceutique française spécialisée dans les contre-mesures médicales de lutte contre les menaces biologiques, annonce aujourd'hui avoir obtenu l'autorisation de mise sur le marché de Ricimed®, un traitement contre l'intoxication à la ricine. Ricimed®, un antidote contre l'une des substances naturelles les plus toxiques au monde En complément des soins de soutien, et dans les conditions graves nécessitant une administration immédiate, Ricime...
-
Samenvatting: Fabentech ontvangt een vergunning om Ricimed® op de markt te brengen, een antidotum tegen ricinevergiftiging
LYON, Frankrijk--(BUSINESS WIRE)--Fabentech, een Frans biofarmaceutisch bedrijf gespecialiseerd in medische tegenmaatregelen tegen biologische bedreigingen, maakte vandaag bekend dat het bedrijf een vergunning werd verleend om Ricimed® op de markt te brengen, een behandeling tegen ricinevergiftiging. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is...
-
Industry Veteran Named as CEO & President of Inland Investments
OAK BROOK, Ill.--(BUSINESS WIRE)--Inland announced that Matthew Fries will serve as CEO and President of Inland Real Estate Investment Corporation (“Inland Investments”)....
-
Capital Engine Announces Strategic Alliance with Regiment to Expand Private Markets Infrastructure and Co-Syndication Capabilities
NEW YORK & CHICAGO--(BUSINESS WIRE)--Capital Engine®, a global FinTech and investment bank building mission-critical infrastructure for the estimated $65 trillion private markets, today announced a strategic alliance with Regiment Securities, LLC (Regiment), a FINRA-registered financial services firm, to expand private-market distribution, co-syndication capabilities, and marketplace connectivity. The alliance is designed to enable the co-syndication of select private investment opportunities a...
-
Blackhawk Network (BHN) Launches Category-Specific Prepaid Rewards Card for Fuel, EV Charging and Grocery Applications
PLEASANTON, Calif.--(BUSINESS WIRE)--Blackhawk Network expands partnership with Mastercard to launch two new filtered prepaid card rewards products....
-
Battelle Awarded Contract Under Defense Microelectronics Activity’s Advanced Technology Support Program
COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle has been selected as one of 10 companies awarded contracts under the Defense Microelectronics Activity’s (DMEA) Advanced Technology Support Program V (ATSP V). The 10-year, government-wide, multiple award Indefinite Delivery/Indefinite Delivery (IDIQ) contract vehicle has a ceiling of $25.35 billion, to rapidly provide engineering solutions for electronics and software problems. Under the contract, Battelle will deliver engineering development capabilit...
-
La France étend l'accès national à l'AAC pour le botensilimab + balstilimab d'Agenus contre le cancer de l'ovaire et les sarcomes des tissus mous
LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq : AGEN), chef de file de l’innovation en immuno-oncologie, annonce aujourd’hui que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) a approuvé un protocole de traitement national actualisé pour le botensilimab (BOT) plus le balstilimab (BAL) dans le cadre de l’autorisation d’accès compassionnel (AAC) en France. Le protocole mis à jour étend l’autorisation précédemment accordée par la France en matière d'A...
-
Needham & Company Hosting the 28th Annual Needham Growth Conference, January 8-16, 2026
NEW YORK--(BUSINESS WIRE)--Needham & Company is hosting its 28th Annual Needham Growth Conference from January 8-16, 2026....